Picture: © Future Insight e.V.

From July 10th to 11th, the multidisciplinary Curious2024 – Future Insight™️ Conference is bringing together some of the world’s brightest scientists, including several Nobel laureates, and the most accomplished innovators to present their work and explore the future of science and technology, solving the challenges of today and enabling the dreams of a better tomorrow.

Leiden-based Amarna Therapeutics welcomed Aurelia Caparrós as its new Chief Business Officer (CBO) in April.

Presentations at Swiss Biotech Day showed that Switzerland has been long No.1 in innovation. © Elvin Yılmaz

The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).

Ipsen headquarters in Paris. © Ipsen SA

Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.

Cross-section of the eye. © National Eye Institute.

French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.

Picture: Faron

Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.

Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the  European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).

Micrograph captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland © NIH

Vaccine maker Sumagen Co. Ltd has launched a  cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.
 

Fermenter within Factory01. © Solar Foods Oy

Finnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.

Sepsis patient journey (above) and Adrenomed's solution to the sepsis cascade (below). © Adrenomed AG, Hennigsdorf near Berlin

German AdrenoMed AG has got FDA Fast Track designation for its targeted septic shock medicine enibarcimab that restores endothel integrity.